Latest Regulatory Filings News

BPH Energy’s September quarter report highlights pivotal developments across its investees, from a critical judicial review in offshore petroleum to breakthroughs in AI medical devices and clean hydrogen production.

Netlinkz Limited reports steady customer receipts and strategic investments in its Securelink joint venture, while preparing for an ASX relisting and a rebrand to Securelink Networks Ltd.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Camplify Holdings reports a modest dip in revenue and transaction value due to poor weather, while maintaining positive cash flow and advancing its NSW TAP program rollout.

Ampol Limited reported a robust third quarter in 2025 with refinery margins hitting a notable high, offsetting volume declines and setting the stage for strategic growth.

icetana Limited posted a net operating cash outflow of AUD 1.126 million for the quarter ending September 2025, ending with a cash balance of AUD 2.71 million. The company’s cash runway currently covers approximately one quarter based on existing cash flows.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Fitzroy River Corporation reported steady royalty income for the June quarter and highlighted significant progress on several royalty projects, including government approvals for Buru Energy’s Rafael Gas Project and a major equity raise for Endura Mining’s Snowy River Gold development.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.